Healthcare company Surgery Partners (NASDAQ: SGRY) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 2.7% year on year to $848.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP profit of $0.10 per share was 59.6% above analysts’ consensus estimates.
Is now the time to buy SGRY? Find out in our full research report (it’s free for active Edge members).
Surgery Partners (SGRY) Q2 CY2026 Highlights:
- Revenue: $848.9 million vs analyst estimates of $830.7 million (2.7% year-on-year growth, 2.2% beat)
- Adjusted EPS: $0.10 vs analyst estimates of $0.06 (59.6% beat)
- Adjusted EBITDA: $125.2 million vs analyst estimates of $123.6 million (14.7% margin, 1.3% beat)
- The company reconfirmed its revenue guidance for the full year of $3.4 billion at the midpoint
- EBITDA guidance for the full year is $530 million at the midpoint, in line with analyst expectations
- Operating Margin: 12%, down from 13.5% in the same quarter last year
- Sales Volumes were flat year on year (3.4% in the same quarter last year)
- Market Capitalization: $2.07 billion
StockStory’s Take
Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead of expectations. CEO Eric Evans credited growth in higher-acuity surgical procedures—particularly in orthopedics, vascular, and spine—as a primary driver, despite overall surgical case volumes remaining flat. Management also pointed to the company’s ongoing focus on recruiting new physicians and maintaining strong relationships with clinical partners as factors supporting same-facility revenue growth. Additionally, a shift in payer mix toward more government reimbursement was anticipated and reflected in operating margin trends, which management described as an expected outcome of the evolving business mix.
Looking ahead, Surgery Partners’ full-year outlook is anchored by its pending divestiture of the Idaho Falls market, which management believes will streamline operations and sharpen the company’s focus on its core short-stay surgical business. CFO David Doherty stated, “We expect this transaction to simplify our business and reduce our exposure to non-core service lines and Medicaid reimbursement risk.” Management expects future growth to be driven by increased recruitment of physicians, targeted development of new ambulatory surgical centers, and disciplined M&A activity, while remaining vigilant about operating costs and payer mix dynamics in an evolving reimbursement landscape.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to higher-acuity procedures, strategic physician recruitment, and the impact of its portfolio optimization initiative, notably the Idaho Falls divestiture.
-
Higher-acuity case focus: The company’s revenue growth was powered by a continued shift toward more complex orthopedic, spine, and vascular surgeries, which tend to yield higher reimbursement per case compared to lower-acuity procedures. CEO Eric Evans noted strong growth in joint, spine, and vascular volumes.
-
Physician recruitment momentum: Management emphasized the addition of 191 new physicians in Q2, with year-to-date recruits contributing 16% more initial revenue compared to last year’s cohort. These new recruits are expected to drive compounding volume and acuity growth over the next several years.
-
Portfolio optimization milestone: The pending sale of the Idaho Falls market to Intermountain Health will eliminate exposure to non-core acute care services such as obstetrics, neonatology, and emergency departments. This is expected to simplify the business and improve cash conversion by reducing capital intensity and Medicaid mix.
-
Payer mix shift as expected: A higher proportion of government-payer reimbursement, especially in larger surgical hospitals, contributed to margin pressure but was planned for in annual forecasts. Management clarified that this dynamic was anticipated and does not signal a change in underlying demand.
-
Disciplined M&A and de novo development: Surgery Partners maintained a cautious approach to acquisitions in the first half of the year, prioritizing balance sheet strength and operational focus. Six new facilities are under construction, and the company continues to vet opportunities that align with its short-stay surgical strategy.
Drivers of Future Performance
Surgery Partners’ outlook is shaped by its narrower portfolio focus, ongoing physician recruitment, and a disciplined approach to growth investments.
-
Core business refocus: With the Idaho Falls divestiture, management expects the company to be more operationally streamlined, reducing exposure to acute care volatility and Medicaid reimbursement risks. This should lead to a more predictable earnings profile and improved cash generation.
-
Growth through partnerships and development: Management plans to drive future revenue through continued physician recruiting, de novo (new facility) development, and select M&A, particularly in the fragmented ambulatory surgery center (ASC) market. CEO Eric Evans emphasized that these strategies, combined with a robust pipeline, are expected to deliver sustainable growth.
-
Ongoing cost management: The company is prioritizing labor, supply, and efficiency initiatives to offset margin headwinds from payer mix shifts and inflationary pressures. COO Justin Oppenheimer highlighted that improvements in salaries, supplies, and G&A as a percentage of revenue are already being realized, with further gains targeted in upcoming quarters.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the closing and subsequent financial impact of the Idaho Falls divestiture and management’s update to full-year guidance, (2) the pace and quality of new physician recruitment and integration, and (3) execution on new ambulatory facility development and selective M&A. Progress on cost control and payer mix management will also be important signals for operating leverage.
Surgery Partners currently trades at $15.94, up from $15.53 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
